ID   LIPL_HUMAN              Reviewed;         475 AA.
AC   P06858; B2R5T9; Q16282; Q16283; Q96FC4;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   10-MAY-2017, entry version 210.
DE   RecName: Full=Lipoprotein lipase;
DE            Short=LPL;
DE            EC=3.1.1.34 {ECO:0000269|PubMed:11342582, ECO:0000269|PubMed:27578112};
DE   Flags: Precursor;
GN   Name=LPL; Synonyms=LIPD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3823907; DOI=10.1126/science.3823907;
RA   Wion K.L., Kirchgessner T.G., Lusis A.J., Schotz M.C., Lawn R.M.;
RT   "Human lipoprotein lipase complementary DNA sequence.";
RL   Science 235:1638-1641(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=2701938; DOI=10.1093/nar/17.6.2351;
RA   Gotoda T., Senda M., Gamou T., Furuichi Y., Oka K.;
RT   "Nucleotide sequence of human cDNA coding for a lipoprotein lipase
RT   (LPL) cloned from placental cDNA library.";
RL   Nucleic Acids Res. 17:2351-2352(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2243796; DOI=10.1093/nar/18.21.6436;
RA   Takagi A., Ikeda Y., Yamamoto A.;
RT   "DNA sequence of lipoprotein lipase cDNA cloned from human monocytic
RT   leukemia THP-1 cells.";
RL   Nucleic Acids Res. 18:6436-6436(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1537564; DOI=10.1016/0378-1119(92)90658-C;
RA   Chuat J.-C., Raisonnier A., Etienne J., Galibert F.;
RT   "The lipoprotein lipase-encoding human gene: sequence from intron-6 to
RT   intron-9 and presence in intron-7 of a 40-million-year-old Alu
RT   sequence.";
RL   Gene 110:257-261(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-318.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-318.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-5.
RX   PubMed=1406652; DOI=10.1128/MCB.12.10.4622;
RA   Enerbaeck S., Ohlsson B.G., Samuelsson L., Bjursell G.;
RT   "Characterization of the human lipoprotein lipase (LPL) promoter:
RT   evidence of two cis-regulatory regions, LP-alpha and LP-beta, of
RT   importance for the differentiation-linked induction of the LPL gene
RT   during adipogenesis.";
RL   Mol. Cell. Biol. 12:4622-4633(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 28-44, AND SUBCELLULAR LOCATION.
RC   TISSUE=Milk;
RX   PubMed=2340307; DOI=10.1016/0005-2760(90)90213-H;
RA   Zechner R.;
RT   "Rapid and simple isolation procedure for lipoprotein lipase from
RT   human milk.";
RL   Biochim. Biophys. Acta 1044:20-25(1990).
RN   [11]
RP   HEPARIN-BINDING, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=11342582; DOI=10.1172/JCI11774;
RA   Lutz E.P., Merkel M., Kako Y., Melford K., Radner H., Breslow J.L.,
RA   Bensadoun A., Goldberg I.J.;
RT   "Heparin-binding defective lipoprotein lipase is unstable and causes
RT   abnormalities in lipid delivery to tissues.";
RL   J. Clin. Invest. 107:1183-1192(2001).
RN   [12]
RP   INTERACTION WITH GPIHBP1.
RX   PubMed=17997385; DOI=10.1016/j.bbalip.2007.10.005;
RA   Gin P., Beigneux A.P., Davies B., Young M.F., Ryan R.O., Bensadoun A.,
RA   Fong L.G., Young S.G.;
RT   "Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to
RT   GPIHBP1 containing a G56R amino acid substitution.";
RL   Biochim. Biophys. Acta 1771:1464-1468(2007).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [14]
RP   3D-STRUCTURE MODELING.
RX   PubMed=8308035;
RA   van Tilbeurgh H., Roussel A., Lalouel J.-M., Cambillau C.;
RT   "Lipoprotein lipase. Molecular model based on the pancreatic lipase X-
RT   ray structure: consequences for heparin binding and catalysis.";
RL   J. Biol. Chem. 269:4626-4633(1994).
RN   [15]
RP   INTERACTION WITH SEL1L AND LMF1.
RX   PubMed=25066055; DOI=10.1016/j.cmet.2014.06.015;
RA   Sha H., Sun S., Francisco A.B., Ehrhardt N., Xue Z., Liu L.,
RA   Lawrence P., Mattijssen F., Guber R.D., Panhwar M.S., Brenna J.T.,
RA   Shi H., Xue B., Kersten S., Bensadoun A., Peterfy M., Long Q., Qi L.;
RT   "The ER-associated degradation adaptor protein Sel1L regulates LPL
RT   secretion and lipid metabolism.";
RL   Cell Metab. 20:458-470(2014).
RN   [16]
RP   REVIEW ON VARIANTS.
RA   Hayden M.R., Ma Y., Brunzell J., Henderson H.E.;
RT   "Genetic variants affecting human lipoprotein and hepatic lipases.";
RL   Curr. Opin. Lipidol. 2:104-109(1991).
RN   [17]
RP   VARIANT LPL DEFICIENCY THR-271, AND INVOLVEMENT IN LPL.
RX   PubMed=2121025;
RA   Hata A., Emi M., Luc G., Basdevant A., Gambert P., Iverius P.-H.,
RA   Lalouel J.-M.;
RT   "Compound heterozygote for lipoprotein lipase deficiency: Ser-->Thr244
RT   and transition in 3' splice site of intron 2 (AG-->AA) in the
RT   lipoprotein lipase gene.";
RL   Am. J. Hum. Genet. 47:721-726(1990).
RN   [18]
RP   VARIANT LPL DEFICIENCY GLU-215.
RX   PubMed=1969408;
RA   Emi M., Wilson D.E., Iverius P.H., Wiu L., Hata A., Hegele R.,
RA   Williams R.R., Lalouel J.-M.;
RT   "Missense mutation (Gly-->Glu188) of human lipoprotein lipase
RT   imparting functional deficiency.";
RL   J. Biol. Chem. 265:5910-5916(1990).
RN   [19]
RP   VARIANT LPL DEFICIENCY GLU-215.
RX   PubMed=1975597; DOI=10.1172/JCI114769;
RA   Monsalve M.V., Henderson H., Roederer G., Julien P., Deeb S.,
RA   Kastelein J.J.P., Peritz L., Devlin R., Bruin T., Murthy M.R.V.,
RA   Gagne C., Davignon J., Lupien P.J., Brunzell J.D., Hayden M.R.;
RT   "A missense mutation at codon 188 of the human lipoprotein lipase gene
RT   is a frequent cause of lipoprotein lipase deficiency in persons of
RT   different ancestries.";
RL   J. Clin. Invest. 86:728-734(1990).
RN   [20]
RP   VARIANT LPL DEFICIENCY THR-203.
RX   PubMed=2110364; DOI=10.1073/pnas.87.9.3474;
RA   Beg O.U., Meng M.S., Skarlatos S.I., Previato L., Brunzell J.D.,
RA   Brewer H.B. Jr., Fojo S.S.;
RT   "Lipoprotein lipase Bethesda: a single amino acid substitution (Ala-
RT   176-->Thr) leads to abnormal heparin binding and loss of enzymic
RT   activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:3474-3478(1990).
RN   [21]
RP   VARIANTS LPL DEFICIENCY THR-221 AND HIS-270.
RX   PubMed=1702428;
RA   Dichek H.L., Fojo S.S., Beg O.U., Skarlatos S.I., Brunzell J.D.,
RA   Cutler G.B. Jr., Brewer H.B. Jr.;
RT   "Identification of two separate allelic mutations in the lipoprotein
RT   lipase gene of a patient with the familial hyperchylomicronemia
RT   syndrome.";
RL   J. Biol. Chem. 266:473-477(1991).
RN   [22]
RP   VARIANT LPL DEFICIENCY GLY-183.
RX   PubMed=1907278;
RA   Faustinella F., Chang A., van Biervliet J.P., Rosseneu M.,
RA   Vinaimont N., Smith L.C., Chen S.-H., Chan L.;
RT   "Catalytic triad residue mutation (Asp156-->Gly) causing familial
RT   lipoprotein lipase deficiency. Co-inheritance with a nonsense mutation
RT   (Ser447-->Ter) in a Turkish family.";
RL   J. Biol. Chem. 266:14418-14424(1991).
RN   [23]
RP   VARIANT LPL DEFICIENCY GLU-169.
RX   PubMed=2010533; DOI=10.1172/JCI115114;
RA   Ameis D., Kobayashi J., Davis R.C., Ben-Zeev O., Malloy M.J.,
RA   Kane J.P., Lee G., Wong H., Havel R.J., Schotz M.C.;
RT   "Familial chylomicronemia (type I hyperlipoproteinemia) due to a
RT   single missense mutation in the lipoprotein lipase gene.";
RL   J. Clin. Invest. 87:1165-1170(1991).
RN   [24]
RP   VARIANT LPL DEFICIENCY THR-221.
RX   PubMed=1674945; DOI=10.1172/JCI115229;
RA   Henderson H.E., Ma Y., Hassan F., Monsalve M.V., Marais A.D.,
RA   Winkler F., Gubernator K., Peterson J., Brunzell J.D., Hayden M.R.;
RT   "Amino acid substitution (Ile194-->Thr) in exon 5 of the lipoprotein
RT   lipase gene causes lipoprotein lipase deficiency in three unrelated
RT   probands. Support for a multicentric origin.";
RL   J. Clin. Invest. 87:2005-2011(1991).
RN   [25]
RP   VARIANTS LPL DEFICIENCY GLU-231 AND HIS-270, AND CHARACTERIZATION OF
RP   VARIANTS LPL DEFICIENCY GLU-231 AND HIS-270.
RX   PubMed=1752947; DOI=10.1172/JCI115507;
RA   Gotoda T., Yamada N., Kawamura M., Kozaki K., Mori N., Ishibashi S.,
RA   Shimano H., Takaku F., Yazaki Y., Furuichi Y., Murase T.;
RT   "Heterogeneous mutations in the human lipoprotein lipase gene in
RT   patients with familial lipoprotein lipase deficiency.";
RL   J. Clin. Invest. 88:1856-1864(1991).
RN   [26]
RP   VARIANT LPL DEFICIENCY LEU-234.
RX   PubMed=2038366; DOI=10.1056/NEJM199106203242502;
RA   Ma Y., Henderson H.E., Ven Murthy M.R., Roederer G., Monsalve M.V.,
RA   Clarke L.A., Normand T., Julien P., Gagne C., Lambert M., Davignon J.,
RA   Lupien P.J., Brunzell J., Hayden M.R.;
RT   "A mutation in the human lipoprotein lipase gene as the most common
RT   cause of familial chylomicronemia in French Canadians.";
RL   N. Engl. J. Med. 324:1761-1766(1991).
RN   [27]
RP   VARIANT LPL DEFICIENCY ARG-113.
RX   PubMed=1598907;
RA   Ishimura-Oka K., Faustinella F., Kihara S., Smith L.C., Oka K.,
RA   Chan L.;
RT   "A missense mutation (Trp86-->Arg) in exon 3 of the lipoprotein lipase
RT   gene: a cause of familial chylomicronemia.";
RL   Am. J. Hum. Genet. 50:1275-1280(1992).
RN   [28]
RP   VARIANT LPL DEFICIENCY ARG-184.
RX   PubMed=1521525; DOI=10.1111/j.1432-1033.1992.tb17182.x;
RA   Bruin T., Kastelein J.J., van Diermen D.E., Ma Y., Henderson H.E.,
RA   Stuyt P.M., Stalenhoef A.F.H., Sturk A., Brunzell J.D., Hayden M.R.;
RT   "A missense mutation Pro157Arg in lipoprotein lipase (LPLNijmegen)
RT   resulting in loss of catalytic activity.";
RL   Eur. J. Biochem. 208:267-272(1992).
RN   [29]
RP   VARIANT LPL DEFICIENCY ASN-277.
RX   PubMed=1639392; DOI=10.1016/0888-7543(92)90136-G;
RA   Ma Y., Wilson B.I., Bijvoet S., Henderson H.E., Cramb E., Roederer G.,
RA   Ven Murthy M.R., Julien P., Bakker H.D., Kastelein J.J.,
RA   Brunzell J.D., Hayden M.R.;
RT   "A missense mutation (Asp250-->Asn) in exon 6 of the human lipoprotein
RT   lipase gene causes chylomicronemia in patients of different
RT   ancestries.";
RL   Genomics 13:649-653(1992).
RN   [30]
RP   VARIANTS LPL DEFICIENCY ASN-183; GLY-183 AND SER-243.
RX   PubMed=1730727;
RA   Ma Y.H., Bruin T., Tuzgol S., Wilson B.I., Roederer G., Liu M.S.,
RA   Davignon J., Kastelein J.J., Brunzell J.D., Hayden M.R.;
RT   "Two naturally occurring mutations at the first and second bases of
RT   codon aspartic acid 156 in the proposed catalytic triad of human
RT   lipoprotein lipase. In vivo evidence that aspartic acid 156 is
RT   essential for catalysis.";
RL   J. Biol. Chem. 267:1918-1923(1992).
RN   [31]
RP   CHARACTERIZATION OF VARIANTS LPL DEFICIENCY ASN-183 AND GLY-183, AND
RP   MUTAGENESIS OF SER-159 AND HIS-268.
RX   PubMed=1371284;
RA   Emmerich J., Beg O.U., Peterson J., Previato L., Brunzell J.D.,
RA   Brewer H.B. Jr., Santamarina-Fojo S.;
RT   "Human lipoprotein lipase. Analysis of the catalytic triad by site-
RT   directed mutagenesis of Ser-132, Asp-156, and His-241.";
RL   J. Biol. Chem. 267:4161-4165(1992).
RN   [32]
RP   VARIANT LPL DEFICIENCY GLU-222.
RX   PubMed=1400331;
RA   Hata A., Ridinger D.N., Sutherland S.D., Emi M., Kwong L.K.,
RA   Shuhua J., Lubbers A., Guy-Grand B., Basdevant A., Iverius P.H.,
RA   Wilson D.E., Lalouel J.-M.;
RT   "Missense mutations in exon 5 of the human lipoprotein lipase gene.
RT   Inactivation correlates with loss of dimerization.";
RL   J. Biol. Chem. 267:20132-20139(1992).
RN   [33]
RP   VARIANTS LPL DEFICIENCY GLU-215; HIS-270 AND ASN-277.
RX   PubMed=1619366;
RA   Ishimura-Oka K., Semenkovich C.F., Faustinella F., Goldberg I.J.,
RA   Shachter N., Smith L.C., Coleman T., Hide W.A., Brown W.V., Oka K.;
RT   "A missense (Asp250-->Asn) mutation in the lipoprotein lipase gene in
RT   two unrelated families with familial lipoprotein lipase deficiency.";
RL   J. Lipid Res. 33:745-754(1992).
RN   [34]
RP   VARIANTS LPL DEFICIENCY ARG-113; ARG-163; GLU-215; THR-221 AND
RP   SER-232.
RX   PubMed=1479292;
RA   Reina M., Brunzell J.D., Deeb S.S.;
RT   "Molecular basis of familial chylomicronemia: mutations in the
RT   lipoprotein lipase and apolipoprotein C-II genes.";
RL   J. Lipid Res. 33:1823-1832(1992).
RN   [35]
RP   VARIANT LPL DEFICIENCY THR-361.
RX   PubMed=8096693; DOI=10.1006/bbrc.1993.1323;
RA   Kobayashi J., Sasaki N., Tashiro J., Inadera H., Saito Y., Yoshida S.;
RT   "A missense mutation (Ala334-->Thr) in exon 7 of the lipoprotein
RT   lipase gene in a case with type I hyperlipidemia.";
RL   Biochem. Biophys. Res. Commun. 191:1046-1054(1993).
RN   [36]
RP   VARIANT LPL DEFICIENCY GLU-207.
RX   PubMed=8288243; DOI=10.1006/geno.1993.1481;
RA   Haubenwallner S., Horl G., Shachter N.S., Presta E., Fried S.K.,
RA   Hofler G., Kostner G.M., Breslow J.L., Zechner R.;
RT   "A novel missense mutation in the gene for lipoprotein lipase
RT   resulting in a highly conservative amino acid substitution
RT   (Asp180-->Glu) causes familial chylomicronemia (type I
RT   hyperlipoproteinemia).";
RL   Genomics 18:392-396(1993).
RN   [37]
RP   VARIANT LPL DEFICIENCY CYS-199.
RX   PubMed=8486765; DOI=10.1172/JCI116414;
RA   Ma Y., Liu M.-S., Ginzinger D., Frohlich J., Brunzell J.D.,
RA   Hayden M.R.;
RT   "Gene-environment interaction in the conversion of a mild-to-severe
RT   phenotype in a patient homozygous for a Ser172-->Cys mutation in the
RT   lipoprotein lipase gene.";
RL   J. Clin. Invest. 91:1953-1958(1993).
RN   [38]
RP   VARIANT LPL DEFICIENCY SER-102.
RX   PubMed=8325986; DOI=10.1172/JCI116551;
RA   Wilson D.E., Hata A., Kwong L.K., Lingam A., Shuhua J., Ridinger D.N.,
RA   Yeager C., Kaltenborn K.C., Iverius P.-H., Lalouel J.-M.;
RT   "Mutations in exon 3 of the lipoprotein lipase gene segregating in a
RT   family with hypertriglyceridemia, pancreatitis, and non-insulin-
RT   dependent diabetes.";
RL   J. Clin. Invest. 92:203-211(1993).
RN   [39]
RP   VARIANT LPL DEFICIENCY SER-181.
RX   PubMed=8301230;
RA   Bruin T., Tuzgol S., van Diermen D.E., Hoogerbrugge-Van der Linden N.,
RA   Brunzell J.D., Hayden M.R., Kastelein J.J.;
RT   "Recurrent pancreatitis and chylomicronemia in an extended Dutch
RT   kindred is caused by a Gly154-->Ser substitution in lipoprotein
RT   lipase.";
RL   J. Lipid Res. 34:2109-2119(1993).
RN   [40]
RP   VARIANT LPL DEFICIENCY VAL-392.
RX   PubMed=8135797; DOI=10.1006/bbrc.1994.1266;
RA   Chimienti G.P.G., Resta F., di Perma V., Tarricone C., Lovecchio M.,
RA   Collacicco A.M., Capurso A.;
RT   "A new Italian case of lipoprotein lipase deficiency: a Leu365-> Val
RT   change resulting in loss of enzyme activity.";
RL   Biochem. Biophys. Res. Commun. 199:570-576(1994).
RN   [41]
RP   VARIANT LPL DEFICIENCY SER-70, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY SER-70.
RX   PubMed=7999071; DOI=10.1006/bbrc.1994.2694;
RA   Kobayashi J., Inadera H., Fujita Y., Talley G., Morisaki N.,
RA   Yoshida S., Saito Y., Fojo S.S., Brewer H.B. Jr.;
RT   "A naturally occurring mutation at the second base of codon asparagine
RT   43 in the proposed N-linked glycosylation site of human lipoprotein
RT   lipase: in vivo evidence that asparagine 43 is essential for catalysis
RT   and secretion.";
RL   Biochem. Biophys. Res. Commun. 205:506-515(1994).
RN   [42]
RP   VARIANTS LPL DEFICIENCY HIS-270 AND CYS-270.
RX   PubMed=7906986; DOI=10.1002/humu.1380030109;
RA   Ma Y., Liu M.-S., Chitayat D., Bruin T., Beisiegel U., Benlian P.,
RA   Foubert L., De Gennes J.L., Funke H., Forsythe I., Blaichman S.,
RA   Papanikolaou M., Erkelens D.W., Kastelein J., Brunzell J.D.,
RA   Hayden M.R.;
RT   "Recurrent missense mutations at the first and second base of codon
RT   Arg243 in human lipoprotein lipase in patients of different
RT   ancestries.";
RL   Hum. Mutat. 3:52-58(1994).
RN   [43]
RP   VARIANTS LPL DEFICIENCY LEU-96 AND GLU-215, AND CHARACTERIZATION OF
RP   VARIANT LPL DEFICIENCY LEU-96.
RX   PubMed=7912254;
RA   Bruin T., Tuzgoel S., Mulder W.J., van den Ende A.E., Jansen H.,
RA   Hayden M.R., Kastelein J.J.P.;
RT   "A compound heterozygote for lipoprotein lipase deficiency,
RT   Val69-->Leu and Gly188-->Glu: correlation between in vitro LPL
RT   activity and clinical expression.";
RL   J. Lipid Res. 35:438-445(1994).
RN   [44]
RP   VARIANTS LPL DEFICIENCY CYS-199; ARG-279; THR-288 AND SER-318, AND
RP   CHARACTERIZATION OF VARIANTS LPL DEFICIENCY ARG-279 AND THR-288.
RX   PubMed=8077845;
RA   Ma Y., Ooi T.C., Liu M.-S., Zhang H., McPherson R., Edwards A.L.,
RA   Forsythe I.J., Frohlich J., Brunzell J.D., Hayden M.R.;
RT   "High frequency of mutations in the human lipoprotein lipase gene in
RT   pregnancy-induced chylomicronemia: possible association with
RT   apolipoprotein E2 isoform.";
RL   J. Lipid Res. 35:1066-1075(1994).
RN   [45]
RP   VARIANT LPL DEFICIENCY VAL-437.
RX   PubMed=7806969;
RA   Previato L., Guardamagna O., Dugi K.A., Ronan R., Talley G.D.,
RA   Santamarina-Fojo S., Brewer H.B. Jr.;
RT   "A novel missense mutation in the C-terminal domain of lipoprotein
RT   lipase (Glu410-->Val) leads to enzyme inactivation and familial
RT   chylomicronemia.";
RL   J. Lipid Res. 35:1552-1560(1994).
RN   [46]
RP   VARIANT LPL DEFICIENCY SER-318.
RX   PubMed=7647785; DOI=10.1038/ng0595-28;
RA   Reymer P.W.A., Gagne E., Groenemeyer B.E., Zhang H., Forsyth I.,
RA   Jansen H., Seidell J.C., Kromhout D., Lie K.E., Kastelein J.J.,
RA   Hayden M.R.;
RT   "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced
RT   HDL cholesterol levels in premature atherosclerosis.";
RL   Nat. Genet. 10:28-34(1995).
RN   [47]
RP   VARIANT LPL DEFICIENCY TYR-445, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY TYR-445.
RX   PubMed=8858123; DOI=10.1006/bbrc.1996.1487;
RA   Henderson H.E., Hassan F., Marais D., Hayden M.R.;
RT   "A new mutation destroying disulphide bridging in the C-terminal
RT   domain of lipoprotein lipase.";
RL   Biochem. Biophys. Res. Commun. 227:189-194(1996).
RN   [48]
RP   VARIANT LPL DEFICIENCY SER-318, AND VARIANT ASN-36.
RX   PubMed=8872057; DOI=10.1111/j.1365-2362.1996.tb02146.x;
RA   de Bruin T.W.A., Mailly F., van Barlingen H.H.J.J., Fisher R.,
RA   Castro Cabezas M., Talmud P., Dallinga-Thie G.M., Humphries S.E.;
RT   "Lipoprotein lipase gene mutations D9N and N291S in four pedigrees
RT   with familial combined hyperlipidaemia.";
RL   Eur. J. Clin. Invest. 26:631-639(1996).
RN   [49]
RP   VARIANTS LPL DEFICIENCY ASN-277 AND LYS-437.
RX   PubMed=8956048;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<381::AID-HUMU16>3.0.CO;2-Z;
RA   Wiebusch H., Funke H., Bruin T., Bucher H., von Eckardstein A.,
RA   Kastelein J.J.P., Assmann G.;
RT   "Compound heterozygosity for a known (D250N) and a novel (E410K)
RT   missense mutation in the C-terminal domain of lipoprotein lipase
RT   causes familial chylomicronemia.";
RL   Hum. Mutat. 8:381-383(1996).
RN   [50]
RP   VARIANTS LPL DEFICIENCY GLY-190 AND GLU-215.
RX   PubMed=8956052;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<392::AID-HUMU20>3.0.CO;2-X;
RA   Wiebusch H., Funke H., Santer R., Richter W., Assmann G.;
RT   "A novel missense (E163G) mutation in the catalytic subunit of
RT   lipoprotein lipase causes familial chylomicronemia.";
RL   Hum. Mutat. 8:392-392(1996).
RN   [51]
RP   VARIANT LPL DEFICIENCY HIS-289, VARIANT ASN-36, CHARACTERIZATION OF
RP   VARIANT LPL DEFICIENCY HIS-289, AND CHARACTERIZATION OF VARIANT
RP   ASN-36.
RX   PubMed=8728326;
RA   Rouis M., Lohse P., Dugi K.A., Lohse P., Beg O.U., Ronan R.,
RA   Talley G.D., Brunzell J.D., Santamarina-Fojo S.;
RT   "Homozygosity for two point mutations in the lipoprotein lipase (LPL)
RT   gene in a patient with familial LPL deficiency: LPL(Asp9-->Asn,
RT   Tyr262-->His).";
RL   J. Lipid Res. 37:651-661(1996).
RN   [52]
RP   VARIANTS LPL DEFICIENCY ALA-128; GLU-215; ARG-215; CYS-270; ASN-277
RP   AND PRO-313.
RX   PubMed=8778602; DOI=10.1056/NEJM199609193351203;
RA   Benlian P., De Gennes J.L., Foubert L., Zhang H., Gagne S.E.,
RA   Hayden M.;
RT   "Premature atherosclerosis in patients with familial chylomicronemia
RT   caused by mutations in the lipoprotein lipase gene.";
RL   N. Engl. J. Med. 335:848-854(1996).
RN   [53]
RP   VARIANT LPL DEFICIENCY ARG-286.
RX   PubMed=9298816;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:3<179::AID-HUMU1>3.3.CO;2-N;
RA   Foubert L., Bruin T., de Gennes J.-L., Ehrenborg E., Furioli J.,
RA   Kastelein J.J., Benlian P., Hayden M.R.;
RT   "A single Ser259Arg mutation in the gene for lipoprotein lipase causes
RT   chylomicronemia in Moroccans of Berber ancestry.";
RL   Hum. Mutat. 10:179-185(1997).
RN   [54]
RP   VARIANTS.
RX   PubMed=9401010;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:6<465::AID-HUMU8>3.3.CO;2-3;
RA   Mailly F., Palmen J., Muller D.P.R., Gibbs T., Lloyd J., Brunzell J.,
RA   Durrington P., Mitropoulos K., Betteridge J., Watts G., Lithell H.,
RA   Angelico F., Humphries S.E., Talmud P.J.;
RT   "Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene
RT   mutations identified in 20 patients from the UK, Sweden, and Italy.";
RL   Hum. Mutat. 10:465-473(1997).
RN   [55]
RP   VARIANTS LPL DEFICIENCY ALA-128; HIS-183; GLU-215; ARG-215; LEU-234;
RP   CYS-270 AND ASN-277.
RX   PubMed=9279761; DOI=10.1136/jmg.34.8.672;
RA   Foubert L., De Gennes J.L., Lagarde J.P., Ehrenborg E., Raisonnier A.,
RA   Girardet J.P., Hayden M.R., Benlian P.;
RT   "Assessment of French patients with LPL deficiency for French Canadian
RT   mutations.";
RL   J. Med. Genet. 34:672-675(1997).
RN   [56]
RP   VARIANTS LPL DEFICIENCY THR-252 AND HIS-270.
RX   PubMed=9714430;
RX   DOI=10.1002/(SICI)1096-8628(19980724)78:4<313::AID-AJMG1>3.0.CO;2-M;
RA   Henderson H.E., Bijvoet S.M., Mannens M.A.M.M., Bruin T.,
RA   Erkelens D.W., Hayden M.R., Kastelein J.J.P.;
RT   "Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de
RT   novo event.";
RL   Am. J. Med. Genet. 78:313-316(1998).
RN   [57]
RP   VARIANT LPL DEFICIENCY LYS-448, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY LYS-448.
RX   PubMed=9498099; DOI=10.1016/S0009-8981(97)00144-7;
RA   Henderson H., Leisegang F., Hassan F., Hayden M., Marais D.;
RT   "A novel Glu421Lys substitution in the lipoprotein lipase gene in
RT   pregnancy-induced hypertriglyceridemic pancreatitis.";
RL   Clin. Chim. Acta 269:1-12(1998).
RN   [58]
RP   VARIANTS LPL DEFICIENCY GLU-215 AND GLY-286.
RX   PubMed=10660334;
RA   Evans D., Wendt D., Ahle S., Guerra A., Beisiegel U.;
RT   "Compound heterozygosity for a new (S259G) and a previously described
RT   (G188E) mutation in lipoprotein lipase (LPL) as a cause of
RT   chylomicronemia.";
RL   Hum. Mutat. 12:217-217(1998).
RN   [59]
RP   VARIANTS LPL DEFICIENCY THR-288 AND SER-318, AND VARIANT ASN-36.
RX   PubMed=9719626; DOI=10.1006/mgme.1998.2712;
RA   Zhang Q., Liu Y., Liu B.W., Fan P., Cavanna J., Galton D.J.;
RT   "Common genetic variants of lipoprotein lipase and apolipoproteins AI-
RT   CIII that relate to coronary artery disease: a study in Chinese and
RT   European subjects.";
RL   Mol. Genet. Metab. 64:177-183(1998).
RN   [60]
RP   VARIANT LPL DEFICIENCY SER-318, AND VARIANTS MET-370 AND ALA-379.
RX   PubMed=9662394; DOI=10.1038/907;
RA   Nickerson D.A., Taylor S.L., Weiss K.M., Clark A.G., Hutchinson R.G.,
RA   Stengaerd J., Salomaa V., Vartiainen E., Boerwinkle E., Sing C.F.;
RT   "DNA sequence diversity in a 9.7-kb region of the human lipoprotein
RT   lipase gene.";
RL   Nat. Genet. 19:233-240(1998).
RN   [61]
RP   VARIANT THR-427.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [62]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [63]
RP   VARIANT LPL DEFICIENCY LEU-297, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY LEU-297.
RX   PubMed=11068186; DOI=10.1016/S0925-4439(00)00067-3;
RA   Takagi A., Ikeda Y., Takeda E., Yamamoto A.;
RT   "A newly identified lipoprotein lipase (LPL) gene mutation (F270L) in
RT   a Japanese patient with familial LPL deficiency.";
RL   Biochim. Biophys. Acta 1502:433-446(2000).
RN   [64]
RP   VARIANTS LPL DEFICIENCY ARG-132 AND GLU-231, AND CHARACTERIZATION OF
RP   VARIANTS LPL DEFICIENCY ARG-132 AND GLU-231.
RX   PubMed=11099402; DOI=10.1042/cs0990569;
RA   Ikeda Y., Goji K., Takagi A.;
RT   "A compound heterozygote for a novel missense mutation (G105R) in exon
RT   3 and a missense mutation (D204E) in exon 5 of the lipoprotein lipase
RT   gene in a Japanese infant with hyperchylomicronaemia.";
RL   Clin. Sci. 99:569-578(2000).
RN   [65]
RP   VARIANT LPL DEFICIENCY TRP-266.
RX   PubMed=11134145; DOI=10.1210/jcem.85.12.7069;
RA   Hoffmann M.M., Jacob S., Luft D., Schmuelling R.-M., Rett K.,
RA   Maerz W., Haering H.-U., Matthaei S.;
RT   "Type I hyperlipoproteinemia due to a novel loss of function mutation
RT   of lipoprotein lipase, Cys(239)-->Trp, associated with recurrent
RT   severe pancreatitis.";
RL   J. Clin. Endocrinol. Metab. 85:4795-4798(2000).
RN   [66]
RP   VARIANT LPL DEFICIENCY ASP-210, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY ASP-210.
RX   PubMed=10787434;
RA   Hoelzl B., Kraft H.G., Wiebusch H., Sandhofer A., Patsch J.,
RA   Sandhofer F., Paulweber B.;
RT   "Two novel mutations in the lipoprotein lipase gene in a family with
RT   marked hypertriglyceridemia in heterozygous carriers. Potential
RT   interaction with the polymorphic marker D1S104 on chromosome 1q21-
RT   q23.";
RL   J. Lipid Res. 41:734-741(2000).
RN   [67]
RP   VARIANT LPL DEFICIENCY VAL-181, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY VAL-181.
RX   PubMed=11441134;
RA   Ikeda Y., Takagi A., Nakata Y., Sera Y., Hyoudou S., Hamamoto K.,
RA   Nishi Y., Yamamoto A.;
RT   "Novel compound heterozygous mutations for lipoprotein lipase
RT   deficiency. A G-to-T transversion at the first position of exon 5
RT   causing G154V missense mutation and a 5' splice site mutation of
RT   intron 8.";
RL   J. Lipid Res. 42:1072-1081(2001).
RN   [68]
RP   VARIANTS LPL DEFICIENCY THR-98; ILE-208; VAL-279; ARG-279; TYR-310;
RP   ARG-325 AND PHE-365, AND CHARACTERIZATION OF VARIANTS LPL DEFICIENCY
RP   THR-98; ILE-208; VAL-279; ARG-279; TYR-310; ARG-325 AND PHE-365.
RX   PubMed=12204001; DOI=10.1002/humu.9054;
RA   Chan L.Y.S., Lam C.-W., Mak Y.-T., Tomlinson B., Tsang M.-W., Baum L.,
RA   Masarei J.R.L., Pang C.-P.;
RT   "Genotype-phenotype studies of six novel LPL mutations in Chinese
RT   patients with hypertriglyceridemia.";
RL   Hum. Mutat. 20:232-233(2002).
RN   [69]
RP   VARIANT LPL DEFICIENCY PHE-303, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY PHE-303.
RX   PubMed=12641539; DOI=10.1046/j.1365-2362.2003.01129.x;
RA   Saika Y., Sakai N., Takahashi M., Maruyama T., Kihara S., Ouchi N.,
RA   Ishigami M., Hiraoka H., Nakamura T., Yamashita S., Matsuzawa Y.;
RT   "Novel LPL mutation (L303F) found in a patient associated with
RT   coronary artery disease and severe systemic atherosclerosis.";
RL   Eur. J. Clin. Invest. 33:216-222(2003).
RN   [70]
RP   VARIANT LPL DEFICIENCY SER-318, AND VARIANT ASN-36.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [71]
RP   VARIANT LPL DEFICIENCY VAL-201.
RX   PubMed=14984478; DOI=10.1111/j.0009-9163.2004.00205.x;
RA   Abifadel M., Jambart S., Allard D., Rabes J.-P., Varret M., Derre A.,
RA   Chouery E., Salem N., Junien C., Aydenian H., Boileau C.;
RT   "Identification of the first Lebanese mutation in the LPL gene and
RT   description of a rapid detection method.";
RL   Clin. Genet. 65:158-161(2004).
RN   [72]
RP   VARIANTS LPL DEFICIENCY GLU-215 AND ARG-328.
RX   PubMed=15185149; DOI=10.1007/s00431-004-1474-1;
RA   Kavazarakis E., Stabouli S., Gourgiotis D., Roumeliotou K.,
RA   Traeger-Synodinos J., Bossios A., Fretzayas A., Kanavakis E.;
RT   "Severe hypertriglyceridaemia in a Greek infant: a clinical,
RT   biochemical and genetic study.";
RL   Eur. J. Pediatr. 163:462-466(2004).
RN   [73]
RP   VARIANTS LPL DEFICIENCY SER-70; ARG-132; VAL-181; GLU-215; THR-221;
RP   ARG-225; ALA-227; GLU-231; CYS-270; HIS-270; THR-288; LEU-297;
RP   ARG-305; PHE-330 AND THR-361.
RX   PubMed=15256764; DOI=10.5551/jat.11.131;
RG   The research committee on primary hyperlipidemia of the ministry of health and welfare of Japan;
RA   Maruyama T., Yamashita S., Matsuzawa Y., Bujo H., Takahashi K.,
RA   Saito Y., Ishibashi S., Ohashi K., Shionoiri F., Gotoda T., Yamada N.,
RA   Kita T.;
RT   "Mutations in Japanese subjects with primary hyperlipidemia -- results
RT   from the Research Committee of the Ministry of Health and Welfare of
RT   Japan since 1996.";
RL   J. Atheroscler. Thromb. 11:131-145(2004).
RN   [74]
RP   VARIANTS LPL DEFICIENCY GLU-186; GLU-215 AND THR-221.
RX   PubMed=15877202; DOI=10.1007/s10545-005-7060-5;
RA   Santer R., Gokcay G., Demirkol M., Gal A., Lukacs Z.;
RT   "Hyperchylomicronaemia due to lipoprotein lipase deficiency as a cause
RT   of false-positive newborn screening for biotinidase deficiency.";
RL   J. Inherit. Metab. Dis. 28:137-140(2005).
RN   [75]
RP   VARIANT LPL DEFICIENCY ARG-404, CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY ARG-404, FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=27578112; DOI=10.1016/j.jacl.2016.02.015;
RA   Pingitore P., Lepore S.M., Pirazzi C., Mancina R.M., Motta B.M.,
RA   Valenti L., Berge K.E., Retterstoel K., Leren T.P., Wiklund O.,
RA   Romeo S.;
RT   "Identification and characterization of two novel mutations in the LPL
RT   gene causing type I hyperlipoproteinemia.";
RL   J. Clin. Lipidol. 10:816-823(2016).
CC   -!- FUNCTION: The primary function of this lipase is the hydrolysis of
CC       triglycerides of circulating chylomicrons and very low density
CC       lipoproteins (VLDL) (PubMed:27578112). Binding to heparin sulfate
CC       proteogylcans at the cell surface is vital to the function. The
CC       apolipoprotein, APOC2, acts as a coactivator of LPL activity in
CC       the presence of lipids on the luminal surface of vascular
CC       endothelium (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:11342582, ECO:0000269|PubMed:27578112}.
CC   -!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a
CC       carboxylate. {ECO:0000269|PubMed:11342582,
CC       ECO:0000269|PubMed:27578112}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with APOC2; the
CC       interaction activates LPL activity in the presence of lipids (By
CC       similarity). Interacts with GPIHBP1 (PubMed:17997385). Interacts
CC       with SEL1L and LMF1 (PubMed:25066055).
CC       {ECO:0000250|UniProtKB:P11151, ECO:0000250|UniProtKB:P11152,
CC       ECO:0000269|PubMed:17997385, ECO:0000269|PubMed:25066055}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Lipid-anchor,
CC       GPI-anchor {ECO:0000250}. Secreted {ECO:0000269|PubMed:2340307,
CC       ECO:0000269|PubMed:27578112}. Note=Locates to the plasma membrane
CC       of microvilli of hepatocytes with triacyl-glycerol-rich
CC       lipoproteins (TRL). Some of the bound LPL is then internalized and
CC       located inside non-coated endocytic vesicles (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Tyrosine nitration after lipopolysaccharide (LPS) challenge
CC       down-regulates the lipase activity.
CC       {ECO:0000250|UniProtKB:Q06000}.
CC   -!- DISEASE: Lipoprotein lipase deficiency (LPL deficiency)
CC       [MIM:238600]: Recessive disorder usually manifesting in childhood.
CC       On a normal diet, patients often present with abdominal pain,
CC       hepatosplenomegaly, lipemia retinalis, eruptive xanthomata, and
CC       massive hypertriglyceridemia, sometimes complicated with acute
CC       pancreatitis. {ECO:0000269|PubMed:10660334,
CC       ECO:0000269|PubMed:10787434, ECO:0000269|PubMed:11068186,
CC       ECO:0000269|PubMed:11099402, ECO:0000269|PubMed:11134145,
CC       ECO:0000269|PubMed:11441134, ECO:0000269|PubMed:12204001,
CC       ECO:0000269|PubMed:12641539, ECO:0000269|PubMed:12966036,
CC       ECO:0000269|PubMed:1400331, ECO:0000269|PubMed:1479292,
CC       ECO:0000269|PubMed:14984478, ECO:0000269|PubMed:15185149,
CC       ECO:0000269|PubMed:1521525, ECO:0000269|PubMed:15256764,
CC       ECO:0000269|PubMed:15877202, ECO:0000269|PubMed:1598907,
CC       ECO:0000269|PubMed:1619366, ECO:0000269|PubMed:1639392,
CC       ECO:0000269|PubMed:1674945, ECO:0000269|PubMed:1702428,
CC       ECO:0000269|PubMed:1730727, ECO:0000269|PubMed:1752947,
CC       ECO:0000269|PubMed:1907278, ECO:0000269|PubMed:1969408,
CC       ECO:0000269|PubMed:1975597, ECO:0000269|PubMed:2010533,
CC       ECO:0000269|PubMed:2038366, ECO:0000269|PubMed:2110364,
CC       ECO:0000269|PubMed:2121025, ECO:0000269|PubMed:27578112,
CC       ECO:0000269|PubMed:7647785, ECO:0000269|PubMed:7806969,
CC       ECO:0000269|PubMed:7906986, ECO:0000269|PubMed:7912254,
CC       ECO:0000269|PubMed:7999071, ECO:0000269|PubMed:8077845,
CC       ECO:0000269|PubMed:8096693, ECO:0000269|PubMed:8135797,
CC       ECO:0000269|PubMed:8288243, ECO:0000269|PubMed:8301230,
CC       ECO:0000269|PubMed:8325986, ECO:0000269|PubMed:8486765,
CC       ECO:0000269|PubMed:8728326, ECO:0000269|PubMed:8778602,
CC       ECO:0000269|PubMed:8858123, ECO:0000269|PubMed:8872057,
CC       ECO:0000269|PubMed:8956048, ECO:0000269|PubMed:8956052,
CC       ECO:0000269|PubMed:9279761, ECO:0000269|PubMed:9298816,
CC       ECO:0000269|PubMed:9498099, ECO:0000269|PubMed:9662394,
CC       ECO:0000269|PubMed:9714430, ECO:0000269|PubMed:9719626}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the AB hydrolase superfamily. Lipase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=LPL";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Lipoprotein lipase entry;
CC       URL="https://en.wikipedia.org/wiki/Lipoprotein_lipase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15856; AAB59536.1; -; mRNA.
DR   EMBL; X14390; CAA32564.1; -; mRNA.
DR   EMBL; X54516; CAA38372.1; -; mRNA.
DR   EMBL; M76722; AAA59528.1; -; Genomic_DNA.
DR   EMBL; S76076; AAB21000.1; -; Genomic_DNA.
DR   EMBL; S76077; AAB20999.1; -; Genomic_DNA.
DR   EMBL; BT006726; AAP35372.1; -; mRNA.
DR   EMBL; AK312311; BAG35236.1; -; mRNA.
DR   EMBL; CH471080; EAW63764.1; -; Genomic_DNA.
DR   EMBL; BC011353; AAH11353.1; -; mRNA.
DR   EMBL; X68111; CAA48230.1; -; Genomic_DNA.
DR   CCDS; CCDS6012.1; -.
DR   PIR; A26082; LIHUL.
DR   RefSeq; NP_000228.1; NM_000237.2.
DR   UniGene; Hs.180878; -.
DR   ProteinModelPortal; P06858; -.
DR   SMR; P06858; -.
DR   BioGrid; 110205; 18.
DR   IntAct; P06858; 14.
DR   MINT; MINT-1369348; -.
DR   STRING; 9606.ENSP00000309757; -.
DR   BindingDB; P06858; -.
DR   ChEMBL; CHEMBL2060; -.
DR   DrugBank; DB09278; Activated charcoal.
DR   DrugBank; DB06439; Tyloxapol.
DR   SwissLipids; SLP:000000568; -.
DR   ESTHER; human-LPL; Lipoprotein_Lipase.
DR   iPTMnet; P06858; -.
DR   PhosphoSitePlus; P06858; -.
DR   BioMuta; LPL; -.
DR   DMDM; 126314; -.
DR   EPD; P06858; -.
DR   MaxQB; P06858; -.
DR   PaxDb; P06858; -.
DR   PeptideAtlas; P06858; -.
DR   PRIDE; P06858; -.
DR   DNASU; 4023; -.
DR   Ensembl; ENST00000311322; ENSP00000309757; ENSG00000175445.
DR   GeneID; 4023; -.
DR   KEGG; hsa:4023; -.
DR   UCSC; uc003wzk.5; human.
DR   CTD; 4023; -.
DR   DisGeNET; 4023; -.
DR   GeneCards; LPL; -.
DR   GeneReviews; LPL; -.
DR   HGNC; HGNC:6677; LPL.
DR   HPA; HPA048749; -.
DR   MalaCards; LPL; -.
DR   MIM; 238600; phenotype.
DR   MIM; 609708; gene.
DR   neXtProt; NX_P06858; -.
DR   OpenTargets; ENSG00000175445; -.
DR   Orphanet; 309015; Familial lipoprotein lipase deficiency.
DR   Orphanet; 70470; Hyperlipoproteinemia type 5.
DR   PharmGKB; PA232; -.
DR   eggNOG; ENOG410IJUA; Eukaryota.
DR   eggNOG; ENOG4111GMM; LUCA.
DR   GeneTree; ENSGT00760000119069; -.
DR   HOGENOM; HOG000038553; -.
DR   HOVERGEN; HBG002259; -.
DR   InParanoid; P06858; -.
DR   KO; K01059; -.
DR   OMA; ESVANCH; -.
DR   OrthoDB; EOG091G052B; -.
DR   PhylomeDB; P06858; -.
DR   TreeFam; TF324997; -.
DR   BRENDA; 3.1.1.34; 2681.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SIGNOR; P06858; -.
DR   GeneWiki; Lipoprotein_lipase; -.
DR   GenomeRNAi; 4023; -.
DR   PRO; PR:P06858; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000175445; -.
DR   CleanEx; HS_LPL; -.
DR   ExpressionAtlas; P06858; baseline and differential.
DR   Genevisible; P06858; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0042627; C:chylomicron; IEA:UniProtKB-KW.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IEA:UniProtKB-KW.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0004465; F:lipoprotein lipase activity; IDA:UniProtKB.
DR   GO; GO:0004620; F:phospholipase activity; ISS:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0017129; F:triglyceride binding; IEA:Ensembl.
DR   GO; GO:0004806; F:triglyceride lipase activity; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0034371; P:chylomicron remodeling; IC:BHF-UCL.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0055096; P:low-density lipoprotein particle mediated signaling; IMP:BHF-UCL.
DR   GO; GO:0006644; P:phospholipid metabolic process; ISS:BHF-UCL.
DR   GO; GO:0090197; P:positive regulation of chemokine secretion; IMP:BHF-UCL.
DR   GO; GO:0010886; P:positive regulation of cholesterol storage; IMP:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IC:BHF-UCL.
DR   GO; GO:0010890; P:positive regulation of sequestering of triglyceride; IMP:BHF-UCL.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; ISS:AgBase.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0019432; P:triglyceride biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0019433; P:triglyceride catabolic process; IDA:UniProtKB.
DR   GO; GO:0070328; P:triglyceride homeostasis; IGI:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; ISS:BHF-UCL.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   CDD; cd00707; Pancreat_lipase_like; 1.
DR   Gene3D; 2.60.60.20; -; 1.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR013818; Lipase/vitellogenin.
DR   InterPro; IPR016272; Lipase_LIPH.
DR   InterPro; IPR033906; Lipase_N.
DR   InterPro; IPR002330; Lipo_Lipase.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   InterPro; IPR000734; TAG_lipase.
DR   PANTHER; PTHR11610; PTHR11610; 1.
DR   PANTHER; PTHR11610:SF122; PTHR11610:SF122; 1.
DR   Pfam; PF00151; Lipase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PIRSF; PIRSF000865; Lipoprotein_lipase_LIPH; 1.
DR   PRINTS; PR00822; LIPOLIPASE.
DR   PRINTS; PR00821; TAGLIPASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   TIGRFAMs; TIGR03230; lipo_lipase; 1.
DR   PROSITE; PS00120; LIPASE_SER; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chylomicron; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; GPI-anchor; Heparin-binding; Hydrolase; Hyperlipidemia;
KW   Lipid degradation; Lipid metabolism; Lipoprotein; Membrane; Nitration;
KW   Polymorphism; Reference proteome; Secreted; Signal; VLDL.
FT   SIGNAL        1     27       {ECO:0000269|PubMed:2340307}.
FT   CHAIN        28    475       Lipoprotein lipase.
FT                                /FTId=PRO_0000017775.
FT   DOMAIN      341    464       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   REGION      346    441       Heparin-binding. {ECO:0000250}.
FT   ACT_SITE    159    159       Nucleophile.
FT   ACT_SITE    183    183       Charge relay system.
FT   ACT_SITE    268    268       Charge relay system.
FT   MOD_RES     121    121       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:Q06000}.
FT   MOD_RES     191    191       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:Q06000}.
FT   MOD_RES     343    343       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:Q06000}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:18780401}.
FT   CARBOHYD    386    386       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     54     67       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    243    266       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    291    310       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    302    305       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    445    465       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   VARIANT      36     36       D -> N (in LPL deficiency; has
FT                                approximately 80% of the specific
FT                                activity of wild-type enzyme;
FT                                dbSNP:rs1801177).
FT                                {ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:8728326,
FT                                ECO:0000269|PubMed:8872057,
FT                                ECO:0000269|PubMed:9719626}.
FT                                /FTId=VAR_011948.
FT   VARIANT      70     70       N -> S (in LPL deficiency; produces an
FT                                inactive protein which is not secreted
FT                                into the media).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:7999071}.
FT                                /FTId=VAR_057914.
FT   VARIANT      71     71       H -> Q (in dbSNP:rs11542065).
FT                                /FTId=VAR_049819.
FT   VARIANT      96     96       V -> L (in LPL deficiency; gives rise to
FT                                a 80% decrease in specific catalytic
FT                                activity; dbSNP:rs373088068).
FT                                {ECO:0000269|PubMed:7912254}.
FT                                /FTId=VAR_057915.
FT   VARIANT      98     98       A -> T (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; reduces
FT                                the secretion of the mutant protein
FT                                significantly; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct; dbSNP:rs145657341).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057916.
FT   VARIANT     102    102       R -> S (in LPL deficiency;
FT                                dbSNP:rs118204073).
FT                                {ECO:0000269|PubMed:8325986}.
FT                                /FTId=VAR_004211.
FT   VARIANT     113    113       W -> G (in LPL deficiency).
FT                                /FTId=VAR_004212.
FT   VARIANT     113    113       W -> R (in LPL deficiency;
FT                                dbSNP:rs118204069).
FT                                {ECO:0000269|PubMed:1479292,
FT                                ECO:0000269|PubMed:1598907}.
FT                                /FTId=VAR_004213.
FT   VARIANT     128    128       T -> A (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057917.
FT   VARIANT     132    132       G -> R (in LPL deficiency; synthesized as
FT                                a catalytically inactive form).
FT                                {ECO:0000269|PubMed:11099402,
FT                                ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057918.
FT   VARIANT     163    163       H -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:1479292}.
FT                                /FTId=VAR_004214.
FT   VARIANT     169    169       G -> E (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204063).
FT                                {ECO:0000269|PubMed:2010533}.
FT                                /FTId=VAR_004215.
FT   VARIANT     181    181       G -> S (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8301230}.
FT                                /FTId=VAR_004216.
FT   VARIANT     181    181       G -> V (in LPL deficiency; synthesized as
FT                                a catalytically inactive form).
FT                                {ECO:0000269|PubMed:11441134,
FT                                ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057919.
FT   VARIANT     183    183       D -> G (in LPL deficiency; lacks both
FT                                triolein and tributyrin esterase
FT                                activities; dbSNP:rs118204064).
FT                                {ECO:0000269|PubMed:1371284,
FT                                ECO:0000269|PubMed:1730727,
FT                                ECO:0000269|PubMed:1907278}.
FT                                /FTId=VAR_004217.
FT   VARIANT     183    183       D -> H (in LPL deficiency;
FT                                dbSNP:rs781614031).
FT                                {ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057920.
FT   VARIANT     183    183       D -> N (in LPL deficiency; lacks both
FT                                triolein and tributyrin esterase
FT                                activities). {ECO:0000269|PubMed:1371284,
FT                                ECO:0000269|PubMed:1730727}.
FT                                /FTId=VAR_004218.
FT   VARIANT     184    184       P -> R (in LPL deficiency; Nijmegen; loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:1521525}.
FT                                /FTId=VAR_004219.
FT   VARIANT     185    185       A -> T (in LPL deficiency; 3.2% of
FT                                activity; dbSNP:rs748349562).
FT                                /FTId=VAR_004220.
FT   VARIANT     186    186       G -> E (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15877202}.
FT                                /FTId=VAR_057921.
FT   VARIANT     190    190       E -> G (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8956052}.
FT                                /FTId=VAR_057922.
FT   VARIANT     199    199       S -> C (in LPL deficiency; mild
FT                                hypertriglyceridemia; partial activity;
FT                                dbSNP:rs118204072).
FT                                {ECO:0000269|PubMed:8077845,
FT                                ECO:0000269|PubMed:8486765}.
FT                                /FTId=VAR_004221.
FT   VARIANT     201    201       D -> V (in LPL deficiency).
FT                                {ECO:0000269|PubMed:14984478}.
FT                                /FTId=VAR_057923.
FT   VARIANT     203    203       A -> T (in LPL deficiency; Bethesda; loss
FT                                of activity and abnormal heparin binding;
FT                                dbSNP:rs118204056).
FT                                {ECO:0000269|PubMed:2110364}.
FT                                /FTId=VAR_004222.
FT   VARIANT     207    207       D -> E (in LPL deficiency;
FT                                dbSNP:rs118204076).
FT                                {ECO:0000269|PubMed:8288243}.
FT                                /FTId=VAR_004223.
FT   VARIANT     208    208       V -> I (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; has a
FT                                mild effect on the secretion of the
FT                                mutant enzyme; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct; dbSNP:rs568397156).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057924.
FT   VARIANT     210    210       H -> D (in LPL deficiency; complete loss
FT                                of enzyme activity).
FT                                {ECO:0000269|PubMed:10787434}.
FT                                /FTId=VAR_057925.
FT   VARIANT     210    210       H -> Q (in LPL deficiency; loss of
FT                                activity).
FT                                /FTId=VAR_004224.
FT   VARIANT     215    215       G -> E (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204057).
FT                                {ECO:0000269|PubMed:10660334,
FT                                ECO:0000269|PubMed:1479292,
FT                                ECO:0000269|PubMed:15185149,
FT                                ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:15877202,
FT                                ECO:0000269|PubMed:1619366,
FT                                ECO:0000269|PubMed:1969408,
FT                                ECO:0000269|PubMed:1975597,
FT                                ECO:0000269|PubMed:7912254,
FT                                ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:8956052,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_004225.
FT   VARIANT     215    215       G -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057926.
FT   VARIANT     220    220       S -> R (in LPL deficiency; 2.0% of
FT                                activity; dbSNP:rs757546424).
FT                                /FTId=VAR_004226.
FT   VARIANT     221    221       I -> T (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204061).
FT                                {ECO:0000269|PubMed:1479292,
FT                                ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:15877202,
FT                                ECO:0000269|PubMed:1674945,
FT                                ECO:0000269|PubMed:1702428}.
FT                                /FTId=VAR_004227.
FT   VARIANT     222    222       G -> E (in LPL deficiency;
FT                                dbSNP:rs118204075).
FT                                {ECO:0000269|PubMed:1400331}.
FT                                /FTId=VAR_004228.
FT   VARIANT     225    225       K -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057927.
FT   VARIANT     227    227       V -> A (in LPL deficiency;
FT                                dbSNP:rs528243561).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057928.
FT   VARIANT     231    231       D -> E (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204067).
FT                                {ECO:0000269|PubMed:11099402,
FT                                ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:1752947}.
FT                                /FTId=VAR_004229.
FT   VARIANT     232    232       I -> S (in LPL deficiency;
FT                                dbSNP:rs770601263).
FT                                {ECO:0000269|PubMed:1479292}.
FT                                /FTId=VAR_004230.
FT   VARIANT     234    234       P -> L (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204060).
FT                                {ECO:0000269|PubMed:2038366,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_004231.
FT   VARIANT     243    243       C -> S (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:1730727}.
FT                                /FTId=VAR_004232.
FT   VARIANT     252    252       I -> T (in LPL deficiency;
FT                                dbSNP:rs118204080).
FT                                {ECO:0000269|PubMed:9714430}.
FT                                /FTId=VAR_057929.
FT   VARIANT     266    266       C -> W (in LPL deficiency;
FT                                dbSNP:rs118204082).
FT                                {ECO:0000269|PubMed:11134145}.
FT                                /FTId=VAR_057930.
FT   VARIANT     270    270       R -> C (in LPL deficiency;
FT                                dbSNP:rs118204077).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:7906986,
FT                                ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057931.
FT   VARIANT     270    270       R -> H (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204062).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:1619366,
FT                                ECO:0000269|PubMed:1702428,
FT                                ECO:0000269|PubMed:1752947,
FT                                ECO:0000269|PubMed:7906986,
FT                                ECO:0000269|PubMed:9714430}.
FT                                /FTId=VAR_004233.
FT   VARIANT     271    271       S -> T (in LPL deficiency;
FT                                dbSNP:rs28934893).
FT                                {ECO:0000269|PubMed:2121025}.
FT                                /FTId=VAR_004234.
FT   VARIANT     277    277       D -> N (in LPL deficiency; 5% of full
FT                                activity; dbSNP:rs118204068).
FT                                {ECO:0000269|PubMed:1619366,
FT                                ECO:0000269|PubMed:1639392,
FT                                ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:8956048,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_004235.
FT   VARIANT     278    278       S -> C (in LPL deficiency).
FT                                /FTId=VAR_004236.
FT   VARIANT     279    279       L -> R (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; the
FT                                total LPL mass is reduced compared to
FT                                that of the wild-type construct;
FT                                dbSNP:rs35414700).
FT                                {ECO:0000269|PubMed:12204001,
FT                                ECO:0000269|PubMed:8077845}.
FT                                /FTId=VAR_057932.
FT   VARIANT     279    279       L -> V (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; the
FT                                total LPL mass is reduced compared to
FT                                that of the wild-type construct;
FT                                dbSNP:rs371282890).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057933.
FT   VARIANT     286    286       S -> G (in LPL deficiency).
FT                                {ECO:0000269|PubMed:10660334}.
FT                                /FTId=VAR_004237.
FT   VARIANT     286    286       S -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:9298816}.
FT                                /FTId=VAR_004238.
FT   VARIANT     288    288       A -> T (in LPL deficiency; the LPL mass
FT                                level is approximately 67% of the normal;
FT                                the activity is 32% of the nornal;
FT                                dbSNP:rs1800011).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:8077845,
FT                                ECO:0000269|PubMed:9719626}.
FT                                /FTId=VAR_011949.
FT   VARIANT     289    289       Y -> H (in LPL deficiency; no enzyme
FT                                activity). {ECO:0000269|PubMed:8728326}.
FT                                /FTId=VAR_057934.
FT   VARIANT     297    297       F -> L (in LPL deficiency and
FT                                hyperlipidemia; synthesized as a
FT                                catalytically inactive form; total amount
FT                                is almost equal to that of the normal
FT                                enzyme; non-releasable by heparin due to
FT                                the abnormal structure of the mutant
FT                                protein). {ECO:0000269|PubMed:11068186,
FT                                ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057935.
FT   VARIANT     303    303       L -> F (in LPL deficiency; approximately
FT                                6% of normal LPL activity and 40% of LPL
FT                                mass are detected in the patient's
FT                                postheparin plasma; results in the
FT                                production of a functionally inactive
FT                                enzyme). {ECO:0000269|PubMed:12641539}.
FT                                /FTId=VAR_057936.
FT   VARIANT     305    305       C -> R (in LPL deficiency;
FT                                dbSNP:rs773235712).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057937.
FT   VARIANT     310    310       C -> Y (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; reduces
FT                                the secretion of the mutant protein
FT                                significantly; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057938.
FT   VARIANT     313    313       L -> P (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8778602}.
FT                                /FTId=VAR_057939.
FT   VARIANT     318    318       N -> S (in LPL deficiency; loss of
FT                                activity; frequent mutation;
FT                                dbSNP:rs268).
FT                                {ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7647785,
FT                                ECO:0000269|PubMed:8077845,
FT                                ECO:0000269|PubMed:8872057,
FT                                ECO:0000269|PubMed:9662394,
FT                                ECO:0000269|PubMed:9719626,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004239.
FT   VARIANT     325    325       S -> R (in LPL deficiency; has no effect
FT                                on the specific activity of the enzyme;
FT                                has a mild effect on the secretion of the
FT                                mutant enzyme; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct; dbSNP:rs761265900).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057940.
FT   VARIANT     328    328       M -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15185149}.
FT                                /FTId=VAR_057941.
FT   VARIANT     328    328       M -> T (in LPL deficiency).
FT                                /FTId=VAR_004240.
FT   VARIANT     330    330       L -> F (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057942.
FT   VARIANT     330    330       L -> P (in LPL deficiency).
FT                                /FTId=VAR_004241.
FT   VARIANT     361    361       A -> T (in LPL deficiency;
FT                                dbSNP:rs118204071).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:8096693}.
FT                                /FTId=VAR_004242.
FT   VARIANT     365    365       S -> F (in LPL deficiency; increases the
FT                                specific activity of the enzyme; has a
FT                                mild effect on the secretion of the
FT                                mutant enzyme; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct; dbSNP:rs546542623).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057943.
FT   VARIANT     370    370       V -> M (in dbSNP:rs298).
FT                                {ECO:0000269|PubMed:9662394}.
FT                                /FTId=VAR_011950.
FT   VARIANT     379    379       T -> A (in dbSNP:rs300).
FT                                {ECO:0000269|PubMed:9662394}.
FT                                /FTId=VAR_011951.
FT   VARIANT     392    392       L -> V (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204078).
FT                                {ECO:0000269|PubMed:8135797}.
FT                                /FTId=VAR_004243.
FT   VARIANT     404    404       M -> R (in LPL deficiency; decreased
FT                                protein secretion; loss of lipoprotein
FT                                lipase activity).
FT                                {ECO:0000269|PubMed:27578112}.
FT                                /FTId=VAR_077541.
FT   VARIANT     423    424       Missing (in LPL deficiency; affects the
FT                                protein folding).
FT                                /FTId=VAR_004244.
FT   VARIANT     427    427       A -> T (in dbSNP:rs5934).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_011952.
FT   VARIANT     437    437       E -> K (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8956048}.
FT                                /FTId=VAR_004245.
FT   VARIANT     437    437       E -> V (in LPL deficiency).
FT                                {ECO:0000269|PubMed:7806969}.
FT                                /FTId=VAR_004246.
FT   VARIANT     445    445       C -> Y (in LPL deficiency; has 48% of
FT                                normal activity in vitro; decreased
FT                                levels of activity account for by the
FT                                lower protein mass levels of the mutants
FT                                rather than by decreased enzymatic
FT                                activities; dbSNP:rs118204079).
FT                                {ECO:0000269|PubMed:8858123}.
FT                                /FTId=VAR_057944.
FT   VARIANT     448    448       E -> K (in LPL deficiency; results in a
FT                                moderate reduction in catalytic activity;
FT                                dbSNP:rs149089920).
FT                                {ECO:0000269|PubMed:9498099}.
FT                                /FTId=VAR_057945.
FT   MUTAGEN     159    159       S->G: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
FT   MUTAGEN     159    159       S->T: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
FT   MUTAGEN     268    268       H->G: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
FT   MUTAGEN     268    268       H->Q: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
SQ   SEQUENCE   475 AA;  53162 MW;  FBD00FCD334FB8AA CRC64;
     MESKALLVLT LAVWLQSLTA SRGGVAAADQ RRDFIDIESK FALRTPEDTA EDTCHLIPGV
     AESVATCHFN HSSKTFMVIH GWTVTGMYES WVPKLVAALY KREPDSNVIV VDWLSRAQEH
     YPVSAGYTKL VGQDVARFIN WMEEEFNYPL DNVHLLGYSL GAHAAGIAGS LTNKKVNRIT
     GLDPAGPNFE YAEAPSRLSP DDADFVDVLH TFTRGSPGRS IGIQKPVGHV DIYPNGGTFQ
     PGCNIGEAIR VIAERGLGDV DQLVKCSHER SIHLFIDSLL NEENPSKAYR CSSKEAFEKG
     LCLSCRKNRC NNLGYEINKV RAKRSSKMYL KTRSQMPYKV FHYQVKIHFS GTESETHTNQ
     AFEISLYGTV AESENIPFTL PEVSTNKTYS FLIYTEVDIG ELLMLKLKWK SDSYFSWSDW
     WSSPGFAIQK IRVKAGETQK KVIFCSREKV SHLQKGKAPA VFVKCHDKSL NKKSG
//
